Skip to Content
MilliporeSigma
  • Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition.

Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2014-03-19)
Yu Fen Zheng, Soo Hyeon Bae, Eu Jin Choi, Jung Bae Park, Sun Ok Kim, Min Jung Jang, Gyu Hwan Park, Wan Gyoon Shin, Euichaul Oh, Soo Kyung Bae
ABSTRACT

We evaluated the potential of BST204, a purified dry extract of ginseng, to inhibit or induce human liver cytochrome P450 enzymes (CYPs) and UDP-glucuronosyltransferases (UGTs) in vitro to assess its safety. In vitro drug interactions of four bioactive ginsenosides of BST204, S-Rg3, R-Rg3, S-Rh2, and R-Rh2, were also evaluated. We demonstrated that BST204 slightly inhibited CYP2C8, CYP2D6, CYP2C9, and CYP2B6 activities with IC50 values of 17.4, 26.8, 31.5, and 49.7μg/mL, respectively. BST204 also weakly inhibited UGT1A1, UGT1A9, and UGT2B7 activities with IC50 values of 14.5, 26.6, and 31.5μg/mL, respectively. The potential inhibition by BST204 of the three UGT activities might be attributable to S-Rg3, at least in part, as its inhibitory pattern was similar to that of BST204. However, BST204 showed no time-dependent inactivation of the nine CYPs studied. In addition, BST204 did not induce CYP1A2, 2B6, or 3A4/5. On the basis of an in vivo interaction studies, our data strongly suggest that BST204 is unlikely to cause clinically significant drug-drug interactions mediated via inhibition or induction of most CYPs or UGTs involved in drug metabolism in vivo. Our findings offer a clearer understanding and possibility to predict drug-drug interactions for the safe use of BST204 in clinical practice.

MATERIALS
Product Number
Brand
Product Description

Supelco
Theophylline, Pharmaceutical Secondary Standard; Certified Reference Material
Paracetamol, European Pharmacopoeia (EP) Reference Standard
Theophylline, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dextrorphan
Sigma-Aldrich
6-Hydroxychlorzoxazone, ≥98% (HPLC)
Supelco
Phenacetin melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Theophylline, United States Pharmacopeia (USP) Reference Standard
Supelco
Coumarin, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
3-Methylcholanthrene solution, 100 μg/mL in acetonitrile, PESTANAL®, analytical standard
Sigma-Aldrich
Phenacetin, ≥98.0% (HPLC)
Sigma-Aldrich
Rifampicin, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
1-Naphthol, BioXtra, ≥99%
Sigma-Aldrich
1-Naphthol, ReagentPlus®, ≥99%
Sigma-Aldrich
Uridine, ≥99%
Sigma-Aldrich
Theophylline, anhydrous, ≥99%, powder
Sigma-Aldrich
Uridine, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Rifampicin, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
Uridine, BioUltra, ≥99%
Sigma-Aldrich
Coumarin, ≥99% (HPLC)
Coumarin, European Pharmacopoeia (EP) Reference Standard
Propofol, European Pharmacopoeia (EP) Reference Standard
USP
Phenacetin Melting Point Standard, United States Pharmacopeia (USP) Reference Standard
Supelco
Phenacetin, Pharmaceutical Secondary Standard; Certified Reference Material
Coumarin, primary reference standard
Sigma-Aldrich
Rosiglitazone, ≥98% (HPLC)
Sigma-Aldrich
1-Naphthol, puriss. p.a., reag. Ph. Eur., ≥99% (GC)
Supelco
L-Glutamine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Glutamine
Supelco
Acetaminophen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide phosphate sodium salt, pkg of 5 mg (per vial)